OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
July 01, 2021
The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.
June 02, 2021
Cell-free expression is promising in preclinical applications, but still presents challenges to scale up for commercial production.
May 02, 2021
Demand for recombinant microorganism-based cell culture supplements is rising on the back of lower contamination risk.
April 02, 2021
Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.
The innovation of single-use technologies is applicable early on in the manufacturing process.
March 02, 2021
Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.
December 02, 2020
Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.
November 02, 2020
PAT advances are enabling improved process understanding, process control, and error prevention.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.